Autoimmune hepatitis
MONDO:0016264Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma.
Also known as: autoimmune liver disease, autoimmune hepatitis, autoimmune chronic active hepatitis, autoimmune hepatitis with centrilobular necrosis, chronic autoimmune hepatitis, AIH, autoimmune chronic hepatitis
59 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New booster aims to shield the vulnerable from COVID-19
⭐️ VACCINE ⭐️ CompletedThis study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Research…
Phase: PHASE2, PHASE3 • Sponsor: Hipra Scientific, S.L.U • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:38 UTC
-
New drug VIS171 tested in humans for first time – could it tame autoimmune disease?
Disease control CompletedThis early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available ye…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for autoimmune hepatitis patients who fail standard treatment
Disease control CompletedThis study tested a new biologic drug called VAY736 in 68 adults with autoimmune hepatitis who did not get better with or could not tolerate standard treatments. The goal was to see if VAY736 could safely help normalize liver enzyme levels. Participants received either VAY736 or …
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug shows promise for liver disease in early trial
Disease control CompletedThis study tested a new drug called zetomipzomib in 24 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. Participants received either the drug or a placebo along with their usual treatment for 24 weeks, with an option to continue the drug fo…
Phase: PHASE2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Blood filter shows promise for autoimmune patients
Disease control CompletedThis study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…
Phase: NA • Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
New MRI scan could replace liver biopsies
Diagnosis CompletedThis study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on …
Sponsor: Perspectum • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
Lupus drug hydroxychloroquine tested as COVID-19 shield
Prevention CompletedThis completed study looked at whether lupus patients already taking hydroxychloroquine long-term had a lower risk of catching COVID-19 or developing severe symptoms. Researchers compared 552 patients who either took the drug or did not, using blood tests and questionnaires. The …
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
Cutting salt and sugar may tame steroid side effects
Symptom relief CompletedThis study looked at whether a diet low in salt and sugar can reduce common side effects of corticosteroid treatment, such as weight gain, high blood pressure, and diabetes. Fifty adults with autoimmune diseases or asthma who were starting high-dose corticosteroids were randomly …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Scientists hunt for genetic and environmental triggers of rare muscle diseases
Knowledge-focused CompletedThis study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
AI may solve tricky liver diagnosis puzzle
Knowledge-focused CompletedThis study tests whether artificial intelligence can help doctors tell the difference between drug-induced liver injury and autoimmune hepatitis, two conditions that look very similar. Researchers are building a machine learning model using data from over 2,500 patients. If it wo…
Sponsor: Beijing Friendship Hospital • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Massive study reveals COVID-19 risks for autoimmune patients
Knowledge-focused CompletedThis study looked at over 13,000 people with chronic inflammatory rheumatism or autoimmune diseases who had or were suspected to have COVID-19. Researchers tracked how many developed severe COVID-19 requiring intensive care or leading to death. They also examined risk factors lik…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Rituximab infection risk under the microscope
Knowledge-focused CompletedThis completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New drug LAD191 tested for safety in autoimmune patients
Knowledge-focused CompletedThis early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather…
Phase: PHASE1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC